{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:08:55Z","timestamp":1785017335676,"version":"3.55.0"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p> COVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure. COVID-19 has led to more than 6.5 million deaths worldwide. The significant morbidity and mortality due to COVID-19 have resulted in the development of treatment modalities, such as novel antivirals, to reduce hospitalizations and progression of disease. In 2021, the US Food and Drug Administration authorized nirmatrelvir\/ritonavir for emergency use in nonhospitalized patients with COVID-19. Nirmatrelvir is a newly developed protease inhibitor and is combined with a commonly used pharmacokinetic boosting agent, ritonavir. Given the novelty of nirmatrelvir\/ritonavir, potential adverse effects remain uncertain. In this case, we describe a patient who was initiated on a course of nirmatrelvir\/ritonavir and developed symptomatic bradycardia. <\/jats:p>","DOI":"10.1177\/2050313x231168304","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T08:51:18Z","timestamp":1681980678000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Possible nirmatrelvir\/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-3640","authenticated-orcid":false,"given":"Elizabeth","family":"DeMarco","sequence":"first","affiliation":[{"name":"Shore Medical Center, Somers Point, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Turnipseed","sequence":"additional","affiliation":[{"name":"Shore Medical Center, Somers Point, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Clarke","sequence":"additional","affiliation":[{"name":"Shore Medical Center, Somers Point, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan","family":"Qadeer","sequence":"additional","affiliation":[{"name":"Shore Medical Center, Somers Point, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"bibr1-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0138-2021"},{"key":"bibr2-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031716"},{"key":"bibr3-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20"},{"key":"bibr4-2050313X231168304","unstructured":"National Institutes of Health. COVID-19 treatment guidelines panel: coronavirus disease 2019 (COVID-19) treatment guidelines, https:\/\/www.covid19treatmentguidelines.nih.gov\/"},{"key":"bibr5-2050313X231168304","unstructured":"University of Liverpool COVID-19 Drug interaction database, https:\/\/www.covid19-druginteractions.org\/ (accessed 26 January 2023)."},{"key":"bibr6-2050313X231168304","unstructured":"Atorvastatin (Package insert). Dublin, Ireland: Pfizer Inc, 2019."},{"key":"bibr7-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.11.039"},{"key":"bibr8-2050313X231168304","unstructured":"Apixaban (Package insert). New York: Bristol-Myers Squibb, 2021."},{"key":"bibr9-2050313X231168304","unstructured":"Food Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Paxlovid, 2022, https:\/\/www.fda.gov\/media\/155050\/download"},{"key":"bibr10-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01461"},{"key":"bibr11-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"bibr12-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.10.002"},{"key":"bibr13-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585"},{"key":"bibr14-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1111\/pace.13987"},{"key":"bibr15-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2020.05.004"},{"key":"bibr16-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2020.08.002"},{"key":"bibr17-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-0387-4"},{"key":"bibr18-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"bibr19-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"bibr20-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.10.028"},{"key":"bibr21-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.120.008798"},{"key":"bibr22-2050313X231168304","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.743138"}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X231168304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X231168304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X231168304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T23:44:29Z","timestamp":1740959069000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X231168304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":22,"alternative-id":["10.1177\/2050313X231168304"],"URL":"https:\/\/doi.org\/10.1177\/2050313x231168304","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"2050313X231168304"}}